SCHEMBL19419580

SCHEMBL19419580

O=C(CC1(O)C(=O)Nc2c(Cl)ccc(Cl)c21)c1ccc(OC(F)F)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLI1 Q01543 6/20 0.75
EWSR1 Q01844 6/20 0.75
ERG P11308 1/20 0.75
ETV1 P50549 1/20 0.75
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 5/20 0.57
HTT P42858 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MMP8 P22894 7/20 0.46
MMP2 P08253 6/20 0.46
MMP9 P14780 6/20 0.46
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15337357 0.90 FLI1 (0.77) FLI1EWSR1ERGETV1KMT2A
SCHEMBL19829782 0.86 FLI1 (1.00) FLI1EWSR1ERGETV1KMT2A
SCHEMBL19829781 0.86 FLI1 (1.00) FLI1EWSR1ERGETV1KMT2A
SCHEMBL3486735 0.86 FLI1 (1.00) FLI1EWSR1ERGETV1KMT2A
SCHEMBL29399443 0.86 FLI1 (1.00) FLI1EWSR1ERGETV1KMT2A
SCHEMBL15337274 0.84 FLI1 (0.75) FLI1EWSR1ERGETV1KMT2A
SCHEMBL15337268 0.84 FLI1 (0.78) FLI1EWSR1ERGETV1KMT2A
SCHEMBL13253325 0.83 KMT2A (0.84) FLI1EWSR1ERGETV1KMT2A
SCHEMBL13253318 0.83 FLI1 (0.77) FLI1EWSR1ERGETV1KMT2A
SCHEMBL22199725 0.83 FLI1 (0.77) FLI1EWSR1ERGETV1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711008-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2020-07-14 US disclosed
US-20190337951-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2019-11-07 US disclosed
US-10351569-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2019-07-16 US disclosed
US-20170349600-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-12-07 US disclosed
US-20170349600-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-12-07 US disclosed
US-9822122-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2017-11-21 US disclosed
US-9822122-B2 Indoline analogs and uses thereof Oncternal Therapeutics, Inc. (US) 2017-11-21 US disclosed
US-20170283420-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-10-05 US disclosed
US-20170283420-A1 INDOLINE ANALOGS AND USES THEREOF GEORGETOWN UNIVERSITY 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337951-A1 INDOLINE ANALOGS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-10711008-B2 Indoline analogs and uses thereof FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-10351569-B2 Indoline analogs and uses thereof FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-20170283420-A1 INDOLINE ANALOGS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885
US-20170349600-A1 INDOLINE ANALOGS AND USES THEREOF FLI1, EWSR1, IKZF1 FLI1 1/4885EWSR1 2/4885ERG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.